CLSD Bathi resik saben saham (EPS TTM) Clearside Biomedical

Clearside Biomedical is recognized as an expert in innovative drug delivery methods to the posterior segment of the eye. Business efficiency is supported by a precise micro-injection transport system, which ensures raw material integrity and high margins. Physician confidence in suprachoroidal technology confirms the brand's scientific potential. The rolling annual EPS trend demonstrates profit dynamics, where -5.03 represents the latest metric reading.

CLSD Bathi resik saben saham sajrone patang kuartal pungkasan Clearside Corp (04.07.2022 - 13.12.2025)

Clearside Biomedical Inc - rincian analitis lan metrik utama (CLSD)

- rega saham lan prakiraan rega para ahli:

Kutipan saham Clearside Biomedical|CLSD - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Kapitalisasi pasar Clearside Biomedical, Inc.|CLSD - Total Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Clearside Biomedical|CLSD - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku clearsidebio.com|CLSD - Gunggung Aset Perusahaan

- rincian utang lan likuiditas:

Utang marang Ekuitas Clearside Biomedical|CLSD - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Clearside|CLSD - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Clearside Biomedical, Inc.|CLSD - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Clearside Biomedical|Likuiditas cepet clearsidebio.com

- data bathi lan kelipatan valuasi:

CLSD - Asil keuangan resik|Proyeksi bathi mangsa ngarep Clearside Biomedical|CLSD - Periode bali modal bisnis|Pangali Forward P/E Clearside Biomedical, Inc.|CLSD - Rasio P/E diaturake wutah|Pangali EV/EBITDA Clearside Biomedical, Inc.|CLSD - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Clearside Biomedical|CLSD - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan clearsidebio.com|CLSD - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Clearside Biomedical

Analisis dhasar perusahaan:Clearside Biomedical (CLSD)

Net income per share (TTM) reflects the company's annual earnings per unit, adjusted for the total number of outstanding securities. Investors utilize this metric to decouple fundamental growth from short-term market speculation. By analyzing changes in the rolling annual EPS, one can assess the actual efficiency of profit generation. For Clearside Biomedical (CLSD), this indicator is critical when scaling sales of the SCS micro-injector. The trend of this metric confirms the financial stability of the retinal drug delivery technology.

Pesaing Clearside Biomedical (CLSD)